Namyong Kim brings with him more than 15 years of experiences in scientific research and technical management in the development of biotech instrumentation. He holds more than 10 patents and patent applications, and has published a number of scientific publications in peer-reviewed journals.

Prior to coming to Singapore, Namyong was based in the US where he had the opportunity to work with early-stage high-tech ventures and multinational companies. At BioTrove, he led a chemistry group in the development of the OpenArray™ platform, a miniaturized chip-based platform for homogeneous biological assays.

Earlier to that, he worked with the two-cofounders of Arradial as the Director of Chemistry, and contributed to growing the company into a 15-person team. At Agilent Technologies, he worked on the optimization and commercialization of DNA microarrays as a Research Scientist.

Namyong received his PhD in Chemistry from the Massachusetts Institute of Technology (MIT), and his BSc from the Korea Advanced Institute of Science and Technology (KAIST).

DropArray™ technology was developed by a research group led by Dr. Namyong Kim at the Institute of Bioengineering and Nanotechnology (IBN). The group subsequently spun out of the IBN in 2008 and formed Curiox Biosystems, backed primarily by Nanostart AG, a renowned venture capital firm in Germany; and Exploit Technologies, the commercializing arm of A*STAR. In 2010, Curiox received a large corporate investment by the Zicom Group, a Singaporean/ Australian conglomerate listed on the Australian Stock Exchange.

The investment by the Zicom group has enabled Curiox to accelerate its product development and its overseas expansion and sales plan.

Namyong Kim brings with him more than 15 years of experiences in scientific research and technical management in the development of biotech instrumentation. He holds more than 10 patents and patent applications, and has published a number of scientific publications in peer-reviewed journals.

Prior to coming to Singapore, Namyong was based in the US where he had the opportunity to work with early-stage high-tech ventures and multinational companies. At BioTrove, he led a chemistry group in the development of the OpenArray™ platform, a miniaturized chip-based platform for homogeneous biological assays.

Earlier to that, he worked with the two-cofounders of Arradial as the Director of Chemistry, and contributed to growing the company into a 15-person team. At Agilent Technologies, he worked on the optimization and commercialization of DNA microarrays as a Research Scientist.

Namyong received his PhD in Chemistry from the Massachusetts Institute of Technology (MIT), and his BSc from the Korea Advanced Institute of Science and Technology (KAIST).

DropArray™ technology was developed by a research group led by Dr. Namyong Kim at the Institute of Bioengineering and Nanotechnology (IBN). The group subsequently spun out of the IBN in 2008 and formed Curiox Biosystems, backed primarily by Nanostart AG, a renowned venture capital firm in Germany; and Exploit Technologies, the commercializing arm of A*STAR. In 2010, Curiox received a large corporate investment by the Zicom Group, a Singaporean/ Australian conglomerate listed on the Australian Stock Exchange.

The investment by the Zicom group has enabled Curiox to accelerate its product development and its overseas expansion and sales plan.

Namyong Kim brings with him more than 15 years of experiences in scientific research and technical management in the development of biotech instrumentation. He holds more than 10 patents and patent applications, and has published a number of scientific publications in peer-reviewed journals.

Prior to coming to Singapore, Namyong was based in the US where he had the opportunity to work with early-stage high-tech ventures and multinational companies. At BioTrove, he led a chemistry group in the development of the OpenArray™ platform, a miniaturized chip-based platform for homogeneous biological assays.

Earlier to that, he worked with the two-cofounders of Arradial as the Director of Chemistry, and contributed to growing the company into a 15-person team. At Agilent Technologies, he worked on the optimization and commercialization of DNA microarrays as a Research Scientist.

Namyong received his PhD in Chemistry from the Massachusetts Institute of Technology (MIT), and his BSc from the Korea Advanced Institute of Science and Technology (KAIST).

DropArray™ technology was developed by a research group led by Dr. Namyong Kim at the Institute of Bioengineering and Nanotechnology (IBN). The group subsequently spun out of the IBN in 2008 and formed Curiox Biosystems, backed primarily by Nanostart AG, a renowned venture capital firm in Germany; and Exploit Technologies, the commercializing arm of A*STAR. In 2010, Curiox received a large corporate investment by the Zicom Group, a Singaporean/ Australian conglomerate listed on the Australian Stock Exchange.

The investment by the Zicom group has enabled Curiox to accelerate its product development and its overseas expansion and sales plan.

Namyong Kim brings with him more than 15 years of experiences in scientific research and technical management in the development of biotech instrumentation. He holds more than 10 patents and patent applications, and has published a number of scientific publications in peer-reviewed journals.

Prior to coming to Singapore, Namyong was based in the US where he had the opportunity to work with early-stage high-tech ventures and multinational companies. At BioTrove, he led a chemistry group in the development of the OpenArray™ platform, a miniaturized chip-based platform for homogeneous biological assays.

Earlier to that, he worked with the two-cofounders of Arradial as the Director of Chemistry, and contributed to growing the company into a 15-person team. At Agilent Technologies, he worked on the optimization and commercialization of DNA microarrays as a Research Scientist.

Namyong received his PhD in Chemistry from the Massachusetts Institute of Technology (MIT), and his BSc from the Korea Advanced Institute of Science and Technology (KAIST).

DropArray™ technology was developed by a research group led by Dr. Namyong Kim at the Institute of Bioengineering and Nanotechnology (IBN). The group subsequently spun out of the IBN in 2008 and formed Curiox Biosystems, backed primarily by Nanostart AG, a renowned venture capital firm in Germany; and Exploit Technologies, the commercializing arm of A*STAR. In 2010, Curiox received a large corporate investment by the Zicom Group, a Singaporean/ Australian conglomerate listed on the Australian Stock Exchange.

The investment by the Zicom group has enabled Curiox to accelerate its product development and its overseas expansion and sales plan.

Namyong Kim brings with him more than 15 years of experiences in scientific research and technical management in the development of biotech instrumentation. He holds more than 10 patents and patent applications, and has published a number of scientific publications in peer-reviewed journals.

Prior to coming to Singapore, Namyong was based in the US where he had the opportunity to work with early-stage high-tech ventures and multinational companies. At BioTrove, he led a chemistry group in the development of the OpenArray™ platform, a miniaturized chip-based platform for homogeneous biological assays.

Earlier to that, he worked with the two-cofounders of Arradial as the Director of Chemistry, and contributed to growing the company into a 15-person team. At Agilent Technologies, he worked on the optimization and commercialization of DNA microarrays as a Research Scientist.

Namyong received his PhD in Chemistry from the Massachusetts Institute of Technology (MIT), and his BSc from the Korea Advanced Institute of Science and Technology (KAIST).

DropArray™ technology was developed by a research group led by Dr. Namyong Kim at the Institute of Bioengineering and Nanotechnology (IBN). The group subsequently spun out of the IBN in 2008 and formed Curiox Biosystems, backed primarily by Nanostart AG, a renowned venture capital firm in Germany; and Exploit Technologies, the commercializing arm of A*STAR. In 2010, Curiox received a large corporate investment by the Zicom Group, a Singaporean/ Australian conglomerate listed on the Australian Stock Exchange.

The investment by the Zicom group has enabled Curiox to accelerate its product development and its overseas expansion and sales plan.

Namyong Kim brings with him more than 15 years of experiences in scientific research and technical management in the development of biotech instrumentation. He holds more than 10 patents and patent applications, and has published a number of scientific publications in peer-reviewed journals.

Prior to coming to Singapore, Namyong was based in the US where he had the opportunity to work with early-stage high-tech ventures and multinational companies. At BioTrove, he led a chemistry group in the development of the OpenArray™ platform, a miniaturized chip-based platform for homogeneous biological assays.

Earlier to that, he worked with the two-cofounders of Arradial as the Director of Chemistry, and contributed to growing the company into a 15-person team. At Agilent Technologies, he worked on the optimization and commercialization of DNA microarrays as a Research Scientist.

Namyong received his PhD in Chemistry from the Massachusetts Institute of Technology (MIT), and his BSc from the Korea Advanced Institute of Science and Technology (KAIST).

DropArray™ technology was developed by a research group led by Dr. Namyong Kim at the Institute of Bioengineering and Nanotechnology (IBN). The group subsequently spun out of the IBN in 2008 and formed Curiox Biosystems, backed primarily by Nanostart AG, a renowned venture capital firm in Germany; and Exploit Technologies, the commercializing arm of A*STAR. In 2010, Curiox received a large corporate investment by the Zicom Group, a Singaporean/ Australian conglomerate listed on the Australian Stock Exchange.

The investment by the Zicom group has enabled Curiox to accelerate its product development and its overseas expansion and sales plan.

Namyong Kim brings with him more than 15 years of experiences in scientific research and technical management in the development of biotech instrumentation. He holds more than 10 patents and patent applications, and has published a number of scientific publications in peer-reviewed journals.

Prior to coming to Singapore, Namyong was based in the US where he had the opportunity to work with early-stage high-tech ventures and multinational companies. At BioTrove, he led a chemistry group in the development of the OpenArray™ platform, a miniaturized chip-based platform for homogeneous biological assays.

Earlier to that, he worked with the two-cofounders of Arradial as the Director of Chemistry, and contributed to growing the company into a 15-person team. At Agilent Technologies, he worked on the optimization and commercialization of DNA microarrays as a Research Scientist.

Namyong received his PhD in Chemistry from the Massachusetts Institute of Technology (MIT), and his BSc from the Korea Advanced Institute of Science and Technology (KAIST).

DropArray™ technology was developed by a research group led by Dr. Namyong Kim at the Institute of Bioengineering and Nanotechnology (IBN). The group subsequently spun out of the IBN in 2008 and formed Curiox Biosystems, backed primarily by Nanostart AG, a renowned venture capital firm in Germany; and Exploit Technologies, the commercializing arm of A*STAR. In 2010, Curiox received a large corporate investment by the Zicom Group, a Singaporean/ Australian conglomerate listed on the Australian Stock Exchange.

The investment by the Zicom group has enabled Curiox to accelerate its product development and its overseas expansion and sales plan.